Ianalumab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Ianalumab (VAY-736) 是一种针对 BAFF-R 的人源化、脱羧化抗体。Ianalumab 能够阻断 BAFF 与 BAFF-R 之间的相互作用，拮抗 BAFF 介导的凋亡保护。Ianalumab 具有抗体依赖性细胞毒性 (ADCC)，依赖于免疫受体酪氨酸激活基序 (ITAM) 介导的效应细胞激活。

Ianalumab (VAY-736) is a humanized, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM).

——

Animal Model:Em-TCL1 adoptive transplant model of murine CLL Dosage:10 mg/kg Administration:Injection; once weekly for 6 weeks Result:Ibrutinib enhanced VAY-736 activity through an ITAM function on NK cells.

——

Others

Other Targets

Others

——

——

1929549-92-7

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years